Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)

被引：0

作者：

Bergmann, L. ^{[1
]}

Donskov, F. ^{[2
]}

Motzer, R. J. ^{[3
]}

Voog, E. ^{[4
]}

Hovey, E. J. ^{[5
]}

Gruellich, C. ^{[6
]}

Nott, L. M. ^{[7
]}

Cuff, K. E. ^{[8
]}

Gil, T. ^{[9
]}

Jensen, N., V ^{[10
]}

Chevreau, C. ^{[11
]}

Negrier, S. ^{[12
]}

Depenbusch, R. ^{[13
]}

Cornelio, I ^{[14
]}

Champsaur, A. ^{[14
]}

Escudier, B. J. ^{[15
]}

Pal, S. K. ^{[16
]}

Powles, T. ^{[17
]}

Choueiri, T. K. ^{[18
]}

机构：

[1] Univ Klin Frankfurt Hosp, Frankfurt, Germany

[2] Aarhus Univ Hosp, Aarhus, Netherlands

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France

[5] Prince Wales Hosp, Sydney, NSW, Australia

[6] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany

[7] Royal Hobart Hosp, Hobart, Tas, Australia

[8] Princess Alexandra Hosp, Woolloongabba, Australia

[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[10] Odense Univ Hosp, Odense, Denmark

[11] IUCT Oncopole Inst Claudius Regaud, Toulouse, France

[12] Ctr Leon Berard, Ctr Reg Lutte Canc, Lyon, France

[13] Onkodok GmbH Dedicated Res Facil, Gutersloh, Germany

[14] Exelixis Inc, San Francisco, CA USA

[15] Gustave Roussy Canc Ctr, Villejuif, France

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Queen Mary Univ London, Barts Canc Inst, London, England

[18] Dana Farber Canc Ctr, Boston, MA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P600

引用

页码：200 / 201

页数：2

共 50 条

[21] Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
Duran, Ignacio
Maroto, Pablo
Suarez, Cristina
Castellano, Daniel E.
Garcia del Muro, Xavier
Costa, Luis
Martin-Couce, Lidia
Benzaghou, Fawzi
Thomas, Stephane
Markby, David W.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[22] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
Powles, Thomas
Escudier, Bernard
Mainwaring, Paul N.
Rini, Brian I.
Donskov, Frede
Hammers, Hans J.
Hutson, Thomas E.
Roth, Bruce
Peltola, Katriina
Lee, Jae Lyun
Heng, Daniel Y. C.
Schmidinger, Manuela
Borgman, Anne
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Tannir, Nizar M.
Motzer, Robert J.
Choueiri, Toni K.
BJU INTERNATIONAL, 2015, 116 : 19 - 19
[23] Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
Schmidinger, M.
Motzer, R. J.
Powles, T.
Escudier, B.
Tannir, N. M.
Mainwaring, P. N.
Rini, B. I.
Hammers, H. J.
Donscov, F.
Roth, B.
Peltola, K.
Lee, J. L.
Heng, D. Y. C.
Aftab, D. T.
Hessel, C.
Scheffold, C.
Schwab, G.
Pal, S.
Hutson, T. E.
Choueiri, T. K.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S187 - S188
[24] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
Choueiri, T.
Escudier, B.
Powles, T.
Mainwaring, P.
Rini, B.
Donskov, F.
Hammers, H.
Hutson, T.
Roth, B.
Peltola, K.
Lee, J. L.
Heng, D.
Schmidinger, M.
Borgman-Hagey, A.
Hessel, C.
Scheffold, C.
Schwab, G.
Tannir, N.
Motzer, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
[25] Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC)
Mainwaring, Paul
Powles, Thomas
Escudier, Bernard J.
Tannir, Nizar M.
Rini, Brian I.
Hammers, Hans J.
Donskov, Frede
Roth, Bruce J.
Peltola, Katriina
Lee, Jae-Lyun
Heng, Daniel Yick Chin
Schmidinger, Manuela
Aftab, Dana T.
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Pal, Sumanta K.
Hutson, Thomas E.
Motzer, Robert J.
Choueiri, Toni K.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 109 - 109
[26] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Tannir, Nizar M.
Powles, Thomas
Escudier, Bernard
Donskov, Frede
Gruenwald, Viktor
Sternberg, Cora N.
Schmidinger, Manuela
Schoeffski, Patrick
Szczylik, Cezary
Peltolta, Katriina
Nosov, Dmitry
Melichar, Bohuslav
Clary, Douglas
Scheffold, Christian
Motzer, Robert J.
Choueiri, Toni K.
KIDNEY CANCER, 2020, 4 (01) : 29 - 39
[27] Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
Hessel, C.
Mangeshkar, M.
Motzer, R. J.
Escudier, B.
Powles, T. B.
Schwab, G.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2016, 27
[28] Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
Powles, Thomas
Motzer, Robert J.
Escudier, Bernard J.
Pal, Sumanta K.
Kollmannsberger, Christian K.
Pikiel, Joanna
Gurney, Howard
Rha, Sun Young
Park, Se Hoon
Geertsen, Poul F.
Gross-Goupil, Marine
Grande, Enrique
Suarez, Cristina
Arroyo, Alan M.
Dean, Mark
George, Daniel
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
Bracarda, S.
Choueiri, T. K.
Powles, T.
Motzer, R. J.
Olencki, T.
Frontera, O. A.
Oudard, S.
Rolland, F.
Tomczak, P.
Castellano, D.
Appleman, L.
Drabkin, H.
Vaena, D.
Milwee, S.
Youkstetter, J.
Escudier, B.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
[30] Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study
Escudier, Bernard J.
Powles, Thomas
Motzer, Robert J.
Olencki, Thomas
Aren, Osvaldo Rudy
Oudard, Stephane
Bracarda, Sergio
Tomczak, Piotr
Castellano, Daniel E.
Appleman, Leonard Joseph
Drabkin, Harry A.
Vaena, Daniel A.
Milwee, Steven
Youkstetter, Jillian
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →